Compass posts positive psilocybin data; Solstice makes $225M debutnews2026-09-09T15:35:07+00:00September 9th, 2026|Endpoints News|
Krazati withdrawal completed; Wegovy trial meets endpoint for kids ages 6 to 12news2026-09-08T15:21:33+00:00September 8th, 2026|Endpoints News|
Pfizer shares ADC rights with Medicus; RevMed updates lung cancer datanews2026-09-03T15:19:01+00:00September 3rd, 2026|Endpoints News|
UK regulator halts sales of Tavneos; UniQure seeks approval for Huntington’s gene therapynews2026-09-02T15:07:53+00:00September 2nd, 2026|Endpoints News|
Mounjaro scores FDA approval to reduce CV risk; Teva to buy an approved drugnews2026-08-28T14:58:50+00:00August 28th, 2026|Endpoints News|
Moderna’s $2B offering; AstraZeneca-Amgen and Biokin chalk up Phase 3 winsnews2026-08-27T14:59:41+00:00August 27th, 2026|Endpoints News|
Haisco grants license to Sentivera; ViiV’s HIV treatment OK’d for newbornsnews2026-08-26T15:16:11+00:00August 26th, 2026|Endpoints News|
J&J’s Imaavy wins label expansion; Two approvals in Japannews2026-08-25T14:44:05+00:00August 25th, 2026|Endpoints News|
TwinStrand wins patent case; GSK’s hepatitis B drug approved in Japannews2026-08-24T15:06:08+00:00August 24th, 2026|Endpoints News|
Genentech invests $750M in new factory; Bavarian Nordic delays Lyme trialnews2026-08-21T14:52:26+00:00August 21st, 2026|Endpoints News|
